Keyphrases
Long-acting Preparation
100%
Long-acting Injectable
100%
Risperidone
100%
Schizophrenia
100%
Injectable Drugs
100%
Patients with Schizophrenia
83%
Trial Network
66%
Objective Comparison
33%
Antipsychotics
33%
New Drugs
33%
Schizoaffective Disorder
33%
Atypical Antipsychotics
33%
Psychotic Relapse
33%
New Preparations
33%
Clinical Practice
16%
Olanzapine Pamoate
16%
Market Saturation
16%
Network Infrastructure
16%
Long-acting Injectable Antipsychotics
16%
Glucose-insulin System
16%
Adverse Events
16%
Time to Relapse
16%
Aggressive Marketing
16%
Unit Management
16%
Manuscript Preparation
16%
Blinded Treatment
16%
Premium Price
16%
Successful Implementation
16%
Clinical Setting
16%
Tolerability
16%
Primary Outcome Measure
16%
Service Utilization
16%
Time Monitoring
16%
Prolactin
16%
Fluphenazine Decanoate
16%
Data Management
16%
High-quality Data
16%
Lipids
16%
Oral Antipsychotics
16%
Repeated Assessment
16%
Politicians
16%
Paliperidone Palmitate
16%
Fast Startup
16%
Wholesale Price
16%
Efficient Data Analysis
16%
Psychopathology
16%
Public Health
16%
Pharmacology, Toxicology and Pharmaceutical Science
Risperidone
100%
Microsphere
100%
Antipsychotic
50%
Atypical Antipsychotics
33%
Schizoaffective Psychosis
33%
Tolerability
16%
Paliperidone
16%
Fluphenazine Decanoate
16%
Prolactin
16%
Adverse Event
16%
Olanzapine
16%
Nursing and Health Professions
Microsphere
100%
Risperidone
100%
Atypical Antipsychotics
33%
Schizoaffective Psychosis
33%
Fluphenazine Decanoate
16%
Prolactin
16%
Clinical Practice
16%
Paliperidone
16%
Olanzapine
16%
Adverse Event
16%